These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 38421941)

  • 1. The expanding role of circulating tumor DNA in resectable non-small cell lung cancer.
    Morgensztern D
    Cancer; 2024 May; 130(10):1730-1732. PubMed ID: 38421941
    [No Abstract]   [Full Text] [Related]  

  • 2. [Research progress of circulating tumor DNA methylation in non-small cell lung cancer].
    Yang Lan L; Chen Bojiang BJ; Li Lei L
    Zhonghua Jie He He Hu Xi Za Zhi; 2018 Dec; 41(12):967-970. PubMed ID: 30522195
    [No Abstract]   [Full Text] [Related]  

  • 3. Implementing circulating tumor DNA as a prognostic biomarker in resectable non-small cell lung cancer.
    Abbosh C; Hodgson D; Doherty GJ; Gale D; Black JRM; Horn L; Reis-Filho JS; Swanton C
    Trends Cancer; 2024 Jul; 10(7):643-654. PubMed ID: 38839544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic implication of methylation-based circulating tumor DNA detection prior to surgery in stage I non-small cell lung cancer.
    Bossé Y; Dasgupta A; Abadier M; Guthrie V; Song F; Saavedra Armero V; Gaudreault N; Orain M; Lamaze FC; Melton C; Nance T; Hung T; Hodgson D; Abbosh C; Joubert P
    Cancer Lett; 2024 Jul; 594():216984. PubMed ID: 38797230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blood-based tumour mutational burden analysis in NSCLC.
    Das M
    Lancet Oncol; 2018 Sep; 19(9):e446. PubMed ID: 30122616
    [No Abstract]   [Full Text] [Related]  

  • 6. Detection and Monitoring of the BRAF Mutation in Circulating Tumor Cells and Circulating Tumor DNA in BRAF-Mutated Lung Adenocarcinoma.
    Guibert N; Pradines A; Casanova A; Farella M; Keller L; Soria JC; Favre G; Mazières J
    J Thorac Oncol; 2016 Sep; 11(9):e109-12. PubMed ID: 27165943
    [No Abstract]   [Full Text] [Related]  

  • 7. Early postoperative plasma circulating tumour DNA for molecular residue disease detection and recurrence risk evaluation in surgical non-small cell lung cancer.
    Tang J; Tian Y; Wang S; Liu Y; Chen M; Yang X; Tong X; Wang M; Zhao Y; Pang J; Ou Q; Chen X
    Clin Transl Med; 2024 Oct; 14(10):e70056. PubMed ID: 39394592
    [No Abstract]   [Full Text] [Related]  

  • 8. Nanoscale extracellular vesicle-derived DNA is superior to circulating cell-free DNA for mutation detection in early-stage non-small-cell lung cancer.
    Wan Y; Liu B; Lei H; Zhang B; Wang Y; Huang H; Chen S; Feng Y; Zhu L; Gu Y; Zhang Q; Ma H; Zheng SY
    Ann Oncol; 2018 Dec; 29(12):2379-2383. PubMed ID: 30339193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Very early response of circulating tumour-derived DNA in plasma predicts efficacy of nivolumab treatment in patients with non-small cell lung cancer.
    Iijima Y; Hirotsu Y; Amemiya K; Ooka Y; Mochizuki H; Oyama T; Nakagomi T; Uchida Y; Kobayashi Y; Tsutsui T; Kakizaki Y; Goto T; Miyashita Y; Omata M
    Eur J Cancer; 2017 Nov; 86():349-357. PubMed ID: 29078173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Letter Regarding "Clinical Utility of Circulating Tumor DNA in Patients With Advanced KRASG12C-Mutated NSCLC Treated With Sotorasib".
    Kosaka N; Kataoka Y
    J Thorac Oncol; 2024 Aug; 19(8):e28. PubMed ID: 39112012
    [No Abstract]   [Full Text] [Related]  

  • 11. Letter Regarding "Clinical Utility of Circulating Tumor DNA in Patients With Advanced KRASG12C-Mutated NSCLC Treated With Sotorasib".
    Ernst SM; von der Thüsen JH; Dubbink HJ; Dingemans AC
    J Thorac Oncol; 2024 Aug; 19(8):e29-e30. PubMed ID: 39112013
    [No Abstract]   [Full Text] [Related]  

  • 12. Single tube liquid biopsy for advanced non-small cell lung cancer.
    de Wit S; Rossi E; Weber S; Tamminga M; Manicone M; Swennenhuis JF; Groothuis-Oudshoorn CGM; Vidotto R; Facchinetti A; Zeune LL; Schuuring E; Zamarchi R; Hiltermann TJN; Speicher MR; Heitzer E; Terstappen LWMM; Groen HJM
    Int J Cancer; 2019 Jun; 144(12):3127-3137. PubMed ID: 30536653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of circulating tumour DNA to identify patients with epidermal growth factor receptor-positive non-small cell lung cancer who might benefit from sequential tyrosine kinase inhibitor treatment.
    Provencio M; Serna-Blasco R; Franco F; Calvo V; Royuela A; Auglytė M; Sánchez-Hernández A; de Julián Campayo M; García-Girón C; Dómine M; Blasco A; Sánchez JM; Oramas J; Bosch-Barrera J; Sala MÁ; Sereno M; Ortega AL; Chara L; Hernández B; Padilla A; Coves J; Blanco R; Balsalobre J; Mielgo X; Bueno C; Jantus-Lewintre E; Molina-Vila MÁ; Romero A
    Eur J Cancer; 2021 May; 149():61-72. PubMed ID: 33831609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clearing of circulating tumour DNA predicts clinical response to first line tyrosine kinase inhibitors in advanced epidermal growth factor receptor mutated non-small cell lung cancer.
    Ebert EBF; McCulloch T; Hansen KH; Linnet H; Sorensen B; Meldgaard P
    Lung Cancer; 2020 Mar; 141():37-43. PubMed ID: 31945708
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comment on "Clinical Utility of Circulating Tumor DNA in Patients With Advanced KRAS(G12C)-Mutated NSCLC Treated With Sotorasib".
    Jiang Y; Zhang L
    J Thorac Oncol; 2024 Sep; 19(9):e43. PubMed ID: 39242149
    [No Abstract]   [Full Text] [Related]  

  • 16. Molecular features of tumor-derived genetic alterations in circulating cell-free DNA in virtue of autopsy analysis.
    Koba H; Kimura H; Yoneda T; Sone T; Ohkura N; Hara J; Hosomichi K; Tajima A; Kasahara K
    Sci Rep; 2021 Apr; 11(1):8398. PubMed ID: 33863951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating tumor DNA to guide diagnosis and treatment of localized and locally advanced non-small cell lung cancer.
    Marinello A; Tagliamento M; Pagliaro A; Conci N; Cella E; Vasseur D; Remon J; Levy A; Dall'Olio FG; Besse B
    Cancer Treat Rev; 2024 Sep; 129():102791. PubMed ID: 38963991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Response to the Letter to the Editor: Comment on "Clinical Utility of Circulating Tumor DNA in Patients With Advanced KRAS(G12C)-Mutated NSCLC Treated With Sotorasib".
    Ernst SM; von der Thüsen JH; Dubbink HJ; Dingemans AC
    J Thorac Oncol; 2024 Sep; 19(9):e44-e45. PubMed ID: 39242150
    [No Abstract]   [Full Text] [Related]  

  • 19. The Role of Circulating Tumor DNA in Lung Cancer: Mutational Analysis, Diagnosis, and Surveillance Now and into the Future.
    Scilla KA; Rolfo C
    Curr Treat Options Oncol; 2019 Jun; 20(7):61. PubMed ID: 31203467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Finding mutations of interest in circulating tumor DNA helps predict immunotherapy response in lung cancer].
    Guibert N; Pradines A; Favre G; Mazières J
    Med Sci (Paris); 2020 May; 36(5):437-439. PubMed ID: 32452359
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.